The winner of this award will be an initiative which has demonstrably worked to deliver on driving equitable access for patients in underserved communities – such includes but is not limited to educational programs, outreach and awareness campaigns, advocacy partnership or research studies that helped to dismantle societal barriers to equitable medicine use.

The winner of this award will be an initiative which has demonstrably worked to deliver clinical trials that excel in enabling diverse patient recruitment and retention. Having identified and addressed key burdens and participation barriers impacting underrepresented demographics, the winning project will have made critical changes to trial design and execution strategies that have quantifiable impact.

The winner of this award will be an individual who has demonstrably worked to reduce patient burden from within a pharmaceutical company, and/or champion a patient community or cause. The winner should be able to show how their actions have advanced benefits to patients or amplified the patient voice within the business; they may be in a patient-facing role or be a ‘back-office ‘unsung hero’ who has driven change that will ultimately address unmet patient needs.

The winner of this award will be an advocate who has amplified the voice of the patient community. This may include supporting new patient community growth or movement, policy change, awareness raising, increased health literacy and education, and launching of a product. The winner must have empowered or motivated others to increase patient visibility and should have collaborated with pharma and/or health organizations to make a difference to key pain points and outcomes.

The winner of this award will be a project or initiative that has advanced patient outreach and engagement, through digital approaches, post launch. It should demonstrate an iterative approach to product development by identifying and addressing real health requirements prior to and during implementation. The winning project will have met a strong patient need and been managed to an outstanding level, making a quantifiable, positive impact on patients.

The winner of this award will be an innovative project which has delivered tangible working and healthcare improvements, both in the long and short term, to healthcare professionals* or to healthcare institutions/systems. Demonstrating understanding of real health requirements prior to implementation, the winning project will have met a strong need and been managed to an outstanding level, making a quantifiable, positive impact on its intended customer. Please indicate how the project generated new knowledge which will ensure long-term impact. 

* including but not limited to physicians, specialists, nurses or payers 

This award is for an initiative that has raised the profile and visibility of a disease, cause, health concern, population or treatment. We are not looking to reward mere advertising (no matter how good it is); we are seeking campaigns which have provided additional value, shown creative ways to raise awareness, gathered further reach in an additional way, clarified scientific concepts for HCPs or patients, or made things easier or clearer. Ultimately, we are looking for an authentic effort to educate and further the understanding of something that matters, and that has achieved success in doing so. 

The winner of this award will be the creator of a pharma-pharma or pharma-NGO, Association or Non-profit initiative which clearly brings a new proposition to either HCPs, payers and/or healthcare systems, creates new value and redefines what is possible in our industry with a degree of lateral thinking. There is no limit to the number of participants, however each collaboration must involve at least one biopharmaceutical company. Please indicate in your entry how you were able to leverage the unique qualities of each partner, and how the collaboration has been managed and presented for maximum impact. 

The winner of this award will be an initiative that has expanded patient access, focusing on value-based access through a partnership with a health plan and/or health system. This may include a range of programs that have led to a successful collaboration with a payor to enhance clinical nuance of prescription drug utilization and/ or remove patient treatment barriers.

The winner of this award will be an initiative which goes beyond the pill, providing a holistic service or solution that provides significant benefit to patients. The initiative may be complimentary to a medicine (perhaps referred Pill+ or a digital medicine) or be entirely independent of a medicine (for example a digital therapeutic), yet still able to demonstrate clinical or other value. It should either have launched, or will be launched imminently but with some in-field exposure. 

This award is for an initiative that harnesses data (internal or RWD), AI, ML or analytics to reveal valuable insights, ultimately resulting in new opportunities for better patient care. We are looking for those who have smartly deployed data or informatics/analysis techniques whether in clinical, commercial, medical or patient-generated data – or who have found ways through data standards or interoperability to enable better insights to be discovered and acted upon. This award is also suitable for those who have created tangible new directions through using AI or distributed ledger (eg blockchain) technology. Ultimately the winner will be able to show the power and ingenuity of what is possible in this burgeoning field. 

The winner of this award will be a pharmaceutical or biotech company, who has demonstrated the most valuable advancement in cell and/or gene therapies. This award seeks to recognise a product or pipeline that is pushing the boundaries of scientific development, providing value to the global healthcare population and addressing the most critically unmet patient needs.

The winner of this award will be a start-up company or entrepreneur who, in a short space of time, has generated strong traction with an original healthcare idea, product or service. We are especially keen on those who have found new ways to serve patients or health professionals in a beneficial way. The winner does not need to have demonstrated commercial success, but will be able to show strong take-up in their venture beyond mere interest. This award primarily seeks to recognize original start-up companies but will also consider spin-out companies and innovative initiatives from larger organisations. 

The winner of this award will be a pharma company, technology provider or data provider, that shows innovation in clinical trials – whether that be through platforms, data usage, digital solutions, analytics, AI/ML or NLP – in order to generate patient-preferred trials. The winner needs to be able to show that they addressed patient needs and addressed them with their solution, and delivered a solution that is beyond standard clinical trial processes and systems.

The winner of this award will be leading an initiative that moves pharma closer to becoming an industry at the forefront of sustainability.  The initiative will demonstrate ambitious goals as well as detailed plans to achieve them. The initiative will also encapsulate changes already implemented by the company, that have had a positive impact on the sustainability of the business.

An award to celebrates individuals in pharma who are being awesome